Loading match intelligence
Resolves Yes if the FDA approves at least one new molecular entity for Alzheimer's disease in 2026, as recorded on the FDA's drug approvals list.
Resolves Yes if Resolves Yes if the FDA approves at least one new molecular entity for Alzheimer's disease in 2026, as recorded on the FDA's drug approvals list.
Outcome verified from fda.gov.
Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.
Analyzing this market…
